The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...
Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback